貨號(hào)
產(chǎn)品規(guī)格
售價(jià)
備注
BN41741R-50ul
50ul
￥1486.00
交叉反應(yīng)：Human,Mouse,Rat 推薦應(yīng)用：WB,IHC-P,IHC-F,IF,ELISA
BN41741R-100ul
100ul
￥2360.00
交叉反應(yīng)：Human,Mouse,Rat 推薦應(yīng)用：WB,IHC-P,IHC-F,IF,ELISA
BN41741R-200ul
200ul
￥3490.00
交叉反應(yīng)：Human,Mouse,Rat 推薦應(yīng)用：WB,IHC-P,IHC-F,IF,ELISA
產(chǎn)品描述
| 英文名稱(chēng) | MEK3 |
| 中文名稱(chēng) | 絲裂原活化蛋白激酶MKK3抗體 |
| 別 名 | MAP Kinase Kinase 3; Dual specificity mitogen activated protein kinase kinase 3; ERK kinase 3; MAP kinase kinase 3; MAP2K 3; MAP2K3; MAPK ERK kinase 3; MAPK kinase 3; MAPKK 3; MAPKK3; MEK 3; Mitogen activated protein kinase kinase 3; MKK 3; MKK3; mMKK 3b; mMKK3b; MPK 3; PRKMK 3; PRKMK3; Protein kinase mitogen activated kinase 3; SKK2; zMKK 3; MP2K3_HUMAN. |
| 研究領(lǐng)域 | 腫瘤 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 細(xì)胞膜受體 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 39kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MKK3:251-347/347 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is activated by mitogenic and environmental stress, and participates in the MAP kinase-mediated signaling cascade. It phosphorylates and thus activates MAPK14/p38-MAPK. This kinase can be activated by insulin, and is necessary for the expression of glucose transporter. Expression of RAS oncogene is found to result in the accumulation of the active form of this kinase, which thus leads to the constitutive activation of MAPK14, and confers oncogenic transformation of primary cells. The inhibition of this kinase is involved in the pathogenesis of Yersina pseudotuberculosis. Multiple alternatively spliced transcript variants that encode distinct isoforms have been reported for this gene. [provided by RefSeq]. Function: The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules. Subunit: Binds to DYRK1B/MIRK and increases its kinase activity. Part of a complex with MAP3K3, RAC1 and CCM2. Interacts with ARRB1. Interacts with Yersinia yopJ. Subcellular Location: Cytoplasm; cytoskeleton. Tissue Specificity: Abundant expression is seen in the skeletal muscle. It is also widely expressed in other tissues. Post-translational modifications: Phosphorylated at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1 or MARK2), causing detachment from microtubules, and their disassembly (By similarity). MAP2A/c is phosphorylated. Phosphorylated upon DNA damage, probably by ATM or ATR. Isoform MAP2c is phosphorylated by FYN at Tyr-67. DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer. Similarity: Contains 3 Tau/MAP repeats. SWISS: P46734 Gene ID: 5606 Database links: Entrez Gene: 5606 Human Entrez Gene: 26397 Mouse Omim: 602315 Human SwissProt: P46734 Human SwissProt: O09110 Mouse Unigene: 514012 Human Unigene: 18494 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
在線(xiàn)咨詢(xún)
English
